2013, Number 3
<< Back Next >>
Med Int Mex 2013; 29 (3)
Nitrosative Stress Detection in Children with Pulmonary Hypertension Secondary to Ventricular Septal Defect
García-Hernández FC, Gutiérrez- Salinas J, García-Ortiz L, Ramírez-García S, Núñez-Ramos NR, Hernández-Rodríguez S, Carranza-Castro H, Archundia-Garcia A
Language: Spanish
References: 30
Page: 242-249
PDF size: 153.63 Kb.
ABSTRACT
Background: Pulmonary hypertension (PH) in children secondary
to ventricular septal defect is a condition that causes changes in the
organism, characterized by hyperactivity in the cardiopulmonary
system. In experimental models it was found that there is nitrosative
stress accompanying the PH. The aim of this study is to detect
this type of metabolic conditions in children with this disease .
Material and Methods: A sample of blood from children (0-5
years old) with the diagnosis of PH secondary to septal defect was
used. With use of spectrophotometric methods, we determine the
concentration of malondialdehyde (MDA), total nitrates (NOx) and
total antioxidant status (TAS). As a control group, children without
cardiovascular disease were sampled age-matched to the group
under study.
Results: The concentration of MDA in children with PH presents a
statistically significant increase, 2.55 times compared to the control
group (p ‹0.05), as did the TAS with increase of 14%. Moreover, the
NOx concentration is 1.42 times lower in patients with PH compared
to control group.
Conclusions: We conclude that children with HP present alterations
in nitrosative balance, indicative of nitrosative stress secondary to
the underlying pathology that can alter the rest of the organism,
especially the circulatory system.
REFERENCES
Rubin L. Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence-based Clinical Practice Guidelines. Chest 2004;126:7-10.
Hipertensión Arterial Pulmonar. Meditex 2002. Documento de consenso de la Sociedad Española de Cardiología y la Sociedad Española de Neumología y Cirugía Torácica, octubre 2001.
Simmonneau G. Continuos Subcutaneous Infusion of treprostinil a Prostacyclin analogue, in patients with pulmonary arterial hypertension. Amer J Resp Crit Care Med 2002;165:800-804.
Santos S, Peinado V. Conceptos actuales sobre la patogenia de la Hipertensión Pulmonar. Arch Bronconeumol 2002;38(supl 1):10-15.
Lobo J. Pauta de tratamiento de la hipertensión pulmonar. Arch Bronconeumol 2002;38(Suppl 1):24-28.
Severson C, McGoon M. Continuous Intravenous Epoprotenol for Pulmonary Arterial Hypertension: Highlightinhg Practical Issues, Special considerations. Advances in Pulmonary Hypertension Winter 2002;1:4-8.
Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheter Cardivasc Interv 2008;71:205-213.
Chin KM, Rubin LJ. Pulmonar artery hypertension. J Am Coll Cardiol 2008;51:1527-1538.
DeMarco VG, Habibi J, Whaley-Connell AT, Schneider RI. Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol 2008;294:H2659-2668.
Ferrari R, Cargnoni A, Curello S, Boffa GM, Ceconi C. Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts. Br J Pharmacol 1989;98:678-684.
Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-514.
Stankevicius E, Kévelaitis E, Vainorius E, Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina 2003;39:333-341.
May JM, Zhi-Chao Q, Xia L, Cobb CE. Nitric uptake and metabolism and oxidant stress in human erythrocytes. Am J Physiol Cell Physiol 2000;279:C1946-C1954.
Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52:601-623.
Noble DR, Williams DLH. Nitrosation products from S-nitrosothiols via preliminary nitric oxide formation. J Chem Soc Perkin Trans 2002;2:1834-1838.
Halliwell B. Free radicals, antioxidants and human disease: curiosity, cause, or consequence? Lancet 1999;344:721-724.
Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997;43:1209-1214.
Fridovich I. Oxygen toxicity: a radical explanation. J Exp Biol 1998;201:1203–1209.
Gutiérez-Salinas J, Cruz-Tovar L. Determinación de enzimas antioxidantes y malondialdehído en el suero de niños con IgM positiva para citomegalovirus Acta Pediatr Mex 2009;30(2):77-83.
Cortas N.K, Wakid N.W. Determination of inorganic nitrate in serum and urine by kinetic cadmium-reduction method. Clin Chem 1990;38:1440-1443.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
Lowry OH, Rosebrough NJ, Farr AI, Randal RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;95:351-358.
Sethi S, Pratap MS, Dikshit M. Nitric oxide-mediated augmentation of polymorphonuclear free radical generation after hypoxia-reoxygenation. Blood 1999;93:333-340.
Yoshida K, Kasama K. Biotransformation of nitric oxide. Eviromental Healt Pers 1987;73:201-206.
Toda N, Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Parmacol Rev 2003;55:271-324.
Rubbo H, Tarpey M, Freeman BA. Nitric oxide and reactive oxygen species in vascular injury. Biochem Soc Symp 2000;61:33-35.
Rathaus M, Bernheim J. Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension. Nephrol Dial Transplant 2002;17:216-221.
Aiko O, Vuopala K, Pokela ML, Hallman M. Diminished inducible nitric oxidase synthase expression in fulminant early-onset neonatal pneumonia. Pediatrics 2000;105:1013-1019.
Anggard E. Nitric oxide: mediator, murderer and medicine. Lancet 1994;343:1199-1206.
Petros A, Bennet D, Vallance P. Effect of nitric oxyde synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-1558.
Full text